REFERENCES
1. ClinicalTrials. gov. Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD (EXPAND). Available from https://clinicaltrials.gov/study/NCT06878560. [accessed 14 August 2026].
2. Pascher A, Sauer IM, Hammer C, Gerlach JC, Neuhaus P. Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience. Xenotransplantation. 2002;9:309-24.
3. Chari RS, Collins BH, Magee JC, et al. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N Engl J Med. 1994;331:234-7.
4. Fieldhouse R. Pig livers for people: US regulator greenlights first safety trial. Nature. 2025;640:870.
5. Shirini K, Ladowski JM, Harsh N, Meier RPH. Xenotransplantation literature update: July-December 2025. Xenotransplantation. 2026;33:e70123.
6. Zhang W, Xu Q, Xu K, et al. Genetically engineered pig-to-human liver xenotransplantation. J Hepatol. 2026;84:587-98.
7. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.
8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315-74.
9. Cillo U, Burra P, Mazzaferro V, et al. ; I-BELT (Italian Board of Experts in the Field of Liver Transplantation). A multistep, consensus-based approach to organ allocation in liver transplantation: toward a “blended principle model”. Am J Transplant. 2015;15:2552-61.
10. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
11. Vitale A, Cabibbo G, Iavarone M, et al. ; HCC Special Interest Group of the Italian Association for the Study of the Liver. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023;24:e312-22.
12. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. 2026;84:631-54.
13. Schaubel DE, Guidinger MK, Biggins SW, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant. 2009;9:970-81.
14. Cillo U, Vitale A, Volk ML, et al. Liver transplantation for T2 hepatocellular carcinoma during the COVID-19 pandemic: a novel model balancing individual benefit against healthcare resources. Cancers. 2021;13:1416.
15. Alonso-Coello P, Schünemann HJ, Moberg J, et al. ; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.
16. Govoni I, Padoan V, Vitale A, et al. ; on behalf of the HCC Special Interest Group of the Italian Association for the Study of the Liver. The role of “treatment unfeasibility” in the multiparametric, multidisciplinary, and expert evaluation of HCC patients. Hepatoma Res. 2026;12:10.
17. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17:S44-57.
18. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587-96.
19. Chen J, Xu X, Wu J, et al. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma. PLoS One. 2014;9:e93128.
20. Duvoux C, Roudot-Thoraval F, Decaens T, et al. ; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986-94.e3.
21. Xiao J, Zeng RW, Lim WH, et al. The incidence of adverse outcome in donors after living donor liver transplantation: a meta-analysis of 60,829 donors. Liver Transpl. 2024;30:493-504.
22. Shaked A, Sagar A, Olthoff KM, et al. Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents. Nat Med. 2026;32:1034-44.
23. Guo Q, Wang C, Mauduit V, et al. Longitudinal multiomics profiling of extracorporeal cross-circulation with pig liver xenografts in human decedents. Nat Med. 2026;32:2970-82.
24. Yau T, Galle PR, Decaens T, et al. ; CheckMate 9DW investigators. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405:1851-64.
25. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345-62.
26. Rezaee-Zavareh MS, Yeo YH, Wang T, et al. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis. J Hepatol. 2025;82:107-19.
27. Tabrizian P, Holzner ML, Ajmera V, et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study. J Hepatol. 2025;82:512-22.
28. Meier RPH. Functional xenogeneic liver support in a living human: promise, lessons, and next steps. Xenotransplantation. 2026;33:e70107.
29. Cross-Najafi AA, Lopez K, Isidan A, et al. Current barriers to clinical liver xenotransplantation. Front Immunol. 2022;13:827535.
30. Wang L, Hara H, Cooper DKC, Wang Y, Wei Q, Xu X. Potential strategies in porcine liver xenotransplantation: a bridge to allotransplantation and beyond. Liver Transpl. 2026;32:256-64.
31. Lim C, Turco C, Balci D, et al. Auxiliary liver transplantation for cirrhosis: from APOLT to RAPID: a scoping review. Ann Surg. 2022;275:551-9.
32. Nastase AG, Vasilescu AM, Trofin AM, et al. Liver xenotransplantation: from early primate trials to the first-in-human porcine bridging therapies. J Clin Med. 2026;15:3144.
33. Cooper DKC. Early clinical xenotransplantation experiences-an interview with Thomas E. Starzl, MD, PhD. Xenotransplantation. 2017;24:e12306.
34. Cooper DKC, Ekser B, Tector AJ. A brief history of clinical xenotransplantation. Int J Surg. 2015;23:205-10.
35. Tao KS, Yang ZX, Zhang X, et al. Gene-modified pig-to-human liver xenotransplantation. Nature. 2025;641:1029-36.
36. Xing K, Chang Y, Zhang X, Du X, Song J. Xenotransplantation in China: past, present, and future. Xenotransplantation. 2025;32:e70038.
